Atracurium Besylate

Atracurium Besylate
Product Description

Atracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent.

It is approved by NMPA.

Read more Show less

Jiangsu Hengrui Medicine Co., Ltd.

  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 5000+
    Employees
Company types
Manufacturer/Innovator
View company profile
Specifications
  • CAS Registry Number
    64228-81-5
  • Supplied from
    China
More specifications Fewer specifications
Sales Markets
Show more Show less

Jiangsu Hengrui Medicine Co., Ltd.

  • CN
  • 2015
    On CPHI since
  • 2
    Certificates
  • 5000+
    Employees
Company types
Manufacturer/Innovator
View company profile

More Products from Jiangsu Hengrui Medicine Co., Ltd. (99)

  • Pramipexole Di-hydrocholoride ER tablets

    Product Pramipexole Di-hydrocholoride ER tablets

    Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement).Strength: 0.375mg, 0.75mg, 1.5mg, 3mg, 4.5mg


    Standard...
  • Pregabalin ER tablets

    Product Pregabalin ER tablets

    Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter. It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions.Strength: 82.5mg, 165mg, 330mg
    Standard: In-house
  • Propofol MCT & LCT emulsion injection

    Product Propofol MCT & LCT emulsion injection

    Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid ...
  • Sevoflurane Inhalation Anesthetic

    Product Sevoflurane Inhalation Anesthetic

    Sevoflurane is a sweet-smelling, nonflammable, highly fluorinated methyl isopropyl ether used as aninhalational anaesthetic for induction and maintenance of general anesthesia.

    Strength: 250ml.


    Sevoflurane Inhalation Anesthetic was approved by NMPA and launc...
  • Desflurane for inhalation

    Product Desflurane for inhalation

    Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anesthesia.

    Strength: 240ml

    It is approved by NMPA.
    It is approved by US-FDA and EU.

  • Dexmedetomidine HCl Injection

    Product Dexmedetomidine HCl Injection

    Dexmedetomide HCl is an anxiolytic, sedative, andanalgesic medication.

    Strength: 200mcg/2ml (100mcg/ml); Single-dose Vial
    This product has been approved by CFDA and US-FDA.

    Strength: 80mcg/20ml; 200mcg/50ml; 400mcg/100ml
    This product has been app...
  • Butorphanol Tartrate

    Product Butorphanol Tartrate

    Butorphanol Tartate is a morphinan-type synthetic opioid analgesic.

    It is approved by NMPA.
  • Salmeterol xinafoate + Fluticasone propionate

    Product Salmeterol xinafoate + Fluticasone propionate

    It is indicated for asthma.It is still in R&D stage.
  • Sugammadex Sodium

    Product Sugammadex Sodium

    Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery in adults.It is still in R&D stage and estimated to be approved by 2020.
  • Paricalcitol

    Product Paricalcitol

    Paricalcitol is a synthetic vitamin D analogue. Paricalcitol has been used to reduce parathyroid hormone levels. It is still in R&D stage, and estimated to be approved by 2020.
  • Ondansetron

    Product Ondansetron

    A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.It is still in R&D stage and estimated to be approved by 2020.
  • Febuxostat

    Product Febuxostat

    Febuxostat is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management.It is still in R&D stage and estimated to be approved by 2020.
show all 99 other products

Jiangsu Hengrui Medicine Co., Ltd. resources (1)